BOLD - Audentes Therapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

BOLD is currently covered by 2 analysts with an average price target of $7.63. This is a potential upside of $6.46 (552.14%) from yesterday's end of day stock price of $1.17.

Audentes Therapeutics's activity chart (see below) currently has 1 price targets and 4 ratings on display. The stock rating distribution of BOLD is 33.33% HOLD and 66.67% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 85.25% with an average time for these price targets to be met of 187.2 days.

Highest price target for BOLD is $3, Lowest price target is $3, average price target is $3.

Most recent stock forecast was given by MICHAEL CHERNY from LEERINK on 28-May-2025. First documented stock forecast 01-May-2017.

Currently out of the existing stock ratings of BOLD, 1 are a HOLD (33.33%), 2 are a BUY (66.67%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold

$3

$1.83 (156.41%)

$25

6 months 16 days ago
(28-May-2025)

0/2 (0%)

$1.8 (150.00%)

Buy

$24

1 years 1 days ago
(13-Dec-2024)

7/8 (87.5%)

$13.99 (139.76%)

90

Buy

$20

$18.86 (1654.39%)

1 years 7 months 22 days ago
(22-Apr-2024)

9/10 (90%)

$9.99 (99.80%)

264

Buy

$48

6 years 10 days ago
(04-Dec-2019)

4/4 (100%)

$9.47 (24.58%)

224

Hold

$45

6 years 12 days ago
(03-Dec-2019)

4/4 (100%)

$8.67 (23.86%)

290

Show more analysts

Please expand the browser size to see the chart

What is BOLD (Audentes Therapeutics) average time for price targets to be met?

On average it took 187.2 days on average for the stock forecasts to be realized with a an average price target met ratio 85.25

Which analyst has the current highest performing score on BOLD (Audentes Therapeutics) with a proven track record?

DAVID NIERENGARTEN

Which analyst has the most public recommendations on BOLD (Audentes Therapeutics)?

David Nierengarten works at WEDBUSH and has 8 price targets and 5 ratings on BOLD

Which analyst is the currently most bullish on BOLD (Audentes Therapeutics)?

Christopher Raymond with highest potential upside - $18.86

Which analyst is the currently most reserved on BOLD (Audentes Therapeutics)?

Joshua Schimmer with lowest potential downside - -$19.97

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?